Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
J
Jicheng Lv
(Renal Division, Peking University First Hospital, Beijing)
L
Lijun Liu
(Protein Structure and X-ray Crystallography Laboratory, Structural Biology Center)
W
Wenxiang Wang
(RemeGen, Yantai, China)
X
Xinyue Wang
Q
Qing Zuraw
(Vor Biopharma, Boston)
V
Vlado Perkovic
(University of New South Wales, Sydney)
J
Jianmin Fang
(RemeGen, Yantai, China)
H
Hong Zhang
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 394, Issue 19
Published
May 14, 2026
Pages
1916-1924
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (8)
J
Jicheng Lv
Renal Division, Peking University First Hospital, Beijing
L
Lijun Liu
Protein Structure and X-ray Crystallography Laboratory, Structural Biology Center
W
Wenxiang Wang
RemeGen, Yantai, China
X
Xinyue Wang
Q
Qing Zuraw
Vor Biopharma, Boston
V
Vlado Perkovic
University of New South Wales, Sydney
J
Jianmin Fang
RemeGen, Yantai, China
H
Hong Zhang
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582